Electromagnetic isotope separation of gadolinium isotopes for the production of 152,155Tb for radiopharmaceutical applications

Köster, U.; Assmann, W.; Bacri, Charles-Olivier; Garrett, P. E.; Gernhäuser, R.; Tomandl, I.

doi:10.1016/j.nimb.2019.07.017

Cited by 15 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the low content of gadolinium-152 (0.2%) in natural gadolinium, natural gadolinium targets are considered unsuitable for the production of terbium-152 for nuclear medicine 32 . Köster et al showed that terbium-152 can be produced with reasonable purity (<1% of terbium-153) by irradiation of highly enriched gadolinium-152 targets (99.9%) at 12 MeV 34 . Moreover, based on the previously obtained data, the radionuclidic purity of terbium-152 can further be improved by reducing the proton beam energy to 10-11 MeV 34 .…”

Section: Radionuclide Properties and Production Methods Of The Four C...mentioning

confidence: 99%

Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

Van Laere,

Koole,

Deroose

et al. 2024

Theranostics

View full text Add to dashboard Cite

Terbium features four clinically interesting radionuclides for application in nuclear medicine: terbium-149, terbium-152, terbium-155, and terbium-161. Their identical chemical properties enable the synthesis of radiopharmaceuticals with the same pharmacokinetic character, while their distinctive decay characteristics make them valuable for both imaging and therapeutic applications. In particular, terbium-152 and terbium-155 are useful candidates for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging, respectively; whereas terbium-149 and terbium-161 find application in α- and β - -/Auger electron therapy, respectively. This unique characteristic makes the terbium family ideal for the “matched-pair” principle of theranostics. In this review, the advantages and challenges of terbium-based radiopharmaceuticals are discussed, covering the entire chain from radionuclide production to bedside administration. It elaborates on the fundamental properties of terbium, the production routes of the four interesting radionuclides and gives an overview of the available bifunctional chelators. Finally, we discuss the preclinical and clinical studies as well as the prospects of this promising development in nuclear medicine.

show abstract

Section: Radionuclide Properties and Production Methods Of The Four C...mentioning

confidence: 99%

Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

Van Laere,

Koole,

Deroose

et al. 2024

Theranostics

View full text Add to dashboard Cite

show abstract

“…However, along with 152 Tb, 153 Tb would be co-produced via 152 Gd(p,γ ) 153 Tb reaction with ∼4 mb cross-section at 8 MeV. Another interesting experiment with comparatively low energy proton for production of 152,155 Tb was carried out in Garching tandem accelerator (35). They produced 152 Tb by irradiating a unique ion-implanted 152 Gd target (enrichment > 99%) with 8 and 12 MeV protons.…”

Section: Production Of Terbium Radionuclides By Light Charged Particle Activationmentioning

confidence: 99%

Theranostic Terbium Radioisotopes: Challenges in Production for Clinical Application

Naskar

Lahiri

2021

Front. Med.

View full text Add to dashboard Cite

Currently, research on terbium has gained a momentum owing to its four short-lived radioisotopes, 149Tb, 152Tb, 155Tb, and 161Tb, all of which can be considered in one or another field of nuclear medicine. The members of this emerging quadruplet family have appealing nuclear characteristics and have the potential to do justice to the proposed theory of theranostics nuclear medicine, which amalgamates therapeutic and diagnostic radioisotopes together. The main challenge for in vivo use of these radioisotopes is to produce them in sufficient quantity. This review discusses that, at present, neither light charged particle nor the heavy ion (HI) activation are suitable for large-scale production of neutron deficient terbium nuclides. Three technological factors like (i) enrichment of stable isotopes to a considerable level, (ii) non-availability of higher energies in commercial cyclotrons, and (iii) non-availability of the isotope separation technique coupled with commercial accelerators limit the large scale production of terbium radionuclides by light charged particle activation. If in future, the technology can overcome these hurdles, then the light charged particle activation of enriched targets would produce a high amount of useful terbium radionuclides. On the other hand, to date, the spallation reaction coupled with an online isotope separator has been found suitable for such a requirement, which has been adopted by the CERN MEDICIS programme. The therapeutic 161Tb radionuclide can be produced in a reactor by neutron bombardment on enriched 160Gd target to produce 161Gd which subsequently decays to 161Tb. The radiochemical separation is mandatory even if the ISOL technique is used to obtain high radioisotopic purity of the desired radioisotope.

show abstract

“…Liquid target systems, while popular for the production of 18 F using enriched water, are also used for the production of radiometals such as 68 Ga, 64 Cu, 61 Cu, 89 Zr, 44 Sc, 86 Y, 63 Zn and 94m Tc [42,43]. They can shorten the pre-and post-irradiation target preparation steps and simplify the target transfer after irradiation [42].…”

Section: Liquid Targetsmentioning

confidence: 99%

“…In this case, the use of mass separators to produce carrier-free radionuclides for nuclear medicine is becoming more and more attractive. However, this method requires large-scale mass separation facilities which are available for this purpose in few places worldwide: MEDICIS at CERN [57][58][59][60][61], ISAC at TRIUMF, Canada [62], FRIB (under construction in Michigan, U.S.A.), ISOL at MYRRHA (under construction in Mol, Belgium) [63] and SPES-INFN (under construction in Legnaro, Italy). At these facilities, radionuclides are produced via high-energy proton induced reactions combined with an online mass separator, known as Isotope Separation On-Line (ISOL).…”

Section: Alternative Production Routesmentioning

confidence: 99%

A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with 68Ga, 44Sc, 177Lu and 161Tb

et al. 2020

View full text Add to dashboard Cite

The production of novel radionuclides is the first step towards the development of new effective radiopharmaceuticals, and the quality thereof directly affects the preclinical and clinical phases. In this review, novel radiometal production for medical applications is briefly elucidated. The production status of the imaging nuclide 44Sc and the therapeutic β--emitter nuclide 161Tb are compared to their more established counterparts, 68Ga and 177Lu according to their targetry, irradiation process, radiochemistry, and quality control aspects. The detailed discussion of these significant issues will help towards the future introduction of these promising radionuclides into drug manufacture for clinical application under Good Manufacturing Practice (GMP).

show abstract

Electromagnetic isotope separation of gadolinium isotopes for the production of 152,155Tb for radiopharmaceutical applications

Cited by 15 publications

References 16 publications

Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

Theranostic Terbium Radioisotopes: Challenges in Production for Clinical Application

A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with 68Ga, 44Sc, 177Lu and 161Tb

Contact Info

Product

Resources

About